Dr. Reddy recalls the wrong Levetiracetam injection in the United States. The patient is likely to experience a ‘disadvantaged’ case.

REDDY’s laboratory is recalling A1540076 of Lot NO: LOT NO: LEVETIRACETAM’s A1540076 0.75% sodium chloride injection, 1,000 mg/100 mL, and a single capacity injection bag in the United States. This product is recalled because the injection bag is incorrectly labeled from 500 mg/100 ml of sodium chloride injection from a single capacity bag to Revecirasetam, and the aluminum excess closed packaging is 0.75% of sodium chloride injection 1,000 mL to livetiracetam accurately identifying the product.

Patients who manage the wrong labeled products can experience side effects according to the risk statement issued by the company.

BECAUSE THE IS LABELLED as 500 mg/100 mL But Actualy Contains 1,000 mg/100 mL dose, The Patient Coul Levetiracetam THICH COULD LEAD Lead to Immediate and Serious Side Effects Including HyperSensitivity Reactions, Liver Injury, Hematological Toxicity, somnolence, fatigue, dizzine, coordination difficulties, agitation, aggression, depressed level of consciousness, respiratory depression and coma.
Patients with high doses of rebecirasatam due to fast venous injection for state epilepsy treatment will be the most dangerous for serious side effects. Dr. S ‘S’ did not receive a report on the side effects related to this recall.

0.75% sodium chloride injection, 1,000 mg/100 ml (10 mg/ml) and 0.82% sodium chloride injection, 500 mg/100 ml (5 mg/ml) Rebecirasetam, Rebecirasetam was found in adult adjunct therapy (≥16).

-Plation seizure
-Fires attack of adolescent myopia epilepsy
-The first generalized tonic attack
Each product is packaged in a single dose injection bag packaged in an aluminum excess type and 10 single capacity bags in the box. Identification information such as a lot number, expiration date and NDC is shown in the table below. The deployment was distributed nationwide nationwide between November 4, 2024 and November 6, 2024.

“Dr. Reddy’s Laboratories, INC is notified to arrange the return of the recalled products to distributors and customers. Through the existing inventory of the recalled rod, it is necessary to replace the replaced products for distribution and distribution of wholesalers, distributors, hospitals and pharmacies. It may have been received.

This recall is being executed with knowledge of the US Food Pharmacy.